Henry Schein, Inc. (NASDAQ:HSIC) Given Average Recommendation of "Moderate Buy" by Brokerages

Key Points

• Analyst sentiment is moderately bullish: Fifteen analysts give Henry Schein a consensus “Moderate Buy” rating, with nine buys, five holds and one sell. The average 12-month price target is $92.93, with recent targets ranging from $82 to $112.
• Quarterly results exceeded expectations: Henry Schein reported $1.27 in quarterly EPS versus the $1.24 consensus estimate and revenue of $3.46 billion, up 6.7% year over year. The company reaffirmed fiscal 2026 EPS guidance of $5.29–$5.39.
• Shares remain near their 12-month high: HSIC opened at $90.39, compared with a 12-month range of $61.94 to $92.18, while institutional investors and hedge funds own 96.62% of the stock.

Shares of Henry Schein, Inc. (NASDAQ:HSIC - Get Free Report) have earned a consensus rating of "Moderate Buy" from the fifteen analysts that are covering the company, Marketbeat reports. One research analyst has rated the stock with a sell recommendation, five have assigned a hold recommendation and nine have assigned a buy recommendation to the company. The average 12-month target price among analysts that have issued ratings on the stock in the last year is $92.9333.

HSIC has been the topic of several analyst reports. Citigroup restated a "buy" rating and set a $112.00 price target (up from $100.00) on shares of Henry Schein in a research report on Wednesday, August 5th. Barclays reissued an "overweight" rating and set a $100.00 target price (up from $86.00) on shares of Henry Schein in a research note on Thursday, August 6th. Mizuho dropped their target price on Henry Schein from $88.00 to $82.00 and set a "neutral" rating on the stock in a research report on Wednesday, May 6th. Weiss Ratings upgraded Henry Schein from a "hold (c+)" rating to a "buy (b-)" rating in a research note on Friday, August 21st. Finally, UBS Group set a $94.00 price target on Henry Schein and gave the stock a "neutral" rating in a report on Wednesday, August 5th.

Henry Schein Trading Up 2.1%

Shares of NASDAQ:HSIC opened at $90.39 on Thursday. Henry Schein has a 12-month low of $61.94 and a 12-month high of $92.18. The company has a market capitalization of $10.07 billion, a PE ratio of 26.35, a PEG ratio of 1.69 and a beta of 0.81. The business has a 50 day moving average of $87.23 and a two-hundred day moving average of $80.19. The company has a current ratio of 1.32, a quick ratio of 0.73 and a debt-to-equity ratio of 0.60.

Henry Schein (NASDAQ:HSIC - Get Free Report) last posted its earnings results on Tuesday, August 4th. The company reported $1.27 earnings per share for the quarter, beating the consensus estimate of $1.24 by $0.03. Henry Schein had a net margin of 2.96% and a return on equity of 15.97%. The firm had revenue of $3.46 billion during the quarter, compared to analyst estimates of $3.37 billion. During the same period in the previous year, the firm earned $1.10 EPS. The business's quarterly revenue was up 6.7% on a year-over-year basis. Henry Schein has set its FY 2026 guidance at 5.290-5.390 EPS. As a group, analysts forecast that Henry Schein will post 5.36 EPS for the current year.

Hedge Funds Weigh In On Henry Schein

Large investors have recently added to or reduced their stakes in the stock. CYBER HORNET ETFs LLC acquired a new position in shares of Henry Schein during the second quarter valued at approximately $25,000. MUFG Securities EMEA plc acquired a new stake in shares of Henry Schein in the second quarter worth approximately $27,000. Federated Hermes Inc. acquired a new stake in shares of Henry Schein in the fourth quarter worth approximately $32,000. Operose Advisors LLC purchased a new stake in shares of Henry Schein during the second quarter worth approximately $33,000. Finally, Los Angeles Capital Management LLC purchased a new stake in shares of Henry Schein during the fourth quarter worth approximately $37,000. 96.62% of the stock is currently owned by institutional investors and hedge funds.

About Henry Schein

Henry Schein, Inc is a leading global distributor of healthcare products and services, primarily serving office-based dental, medical and animal health practitioners. The company operates through three principal segments—Schein Dental, Schein Medical and Animal Health—each offering a comprehensive portfolio of consumable products, equipment, instruments and related value-added services. With a focus on improving practice efficiency and patient care, Henry Schein provides everything from dental restorative materials and orthodontic appliances to vaccines, pharmaceuticals and diagnostic devices for physicians, as well as pet health products and veterinary equipment for animal health professionals.

In addition to its broad product offering, Henry Schein delivers a suite of technology and service solutions aimed at streamlining workflows and enhancing clinical outcomes.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source